, Volume 28, Issue 10, pp 6-11
Date: 18 Dec 2012

Fingolimod: a guide to its use in multiple sclerosis in the EU

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Fingolimod, a novel sphingosine 1-phosphate receptor agonist, is indicated for the treatment of patients with relapsing- remitting multiple sclerosis. In clinical trials, oral fingolimod was more effective than placebo and intramuscular interferon β-1a at reducing annualized relapse rates and the burden and activity of disease.